Platinum‐containing chemotherapy probably leads to higher participants requiring dose reduction compared with chemotherapy without platinum (moderate certainty).
Platinum‐containing chemotherapy probably leads to higher anaemia (grade III/IV) compared with chemotherapy without platinum (moderate certainty).
Platinum‐containing chemotherapy showed no clear difference in febrile neutropenia (grade III/IV) compared with chemotherapy without platinum (moderate certainty).
The review found no eligible studies for this question.
Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).
Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).
Platinum‐containing chemotherapy leads to higher pathological complete response compared with chemotherapy without platinum (high certainty).
Platinum‐containing chemotherapy leads to lower DFS at 2 years compared with chemotherapy without platinum (high certainty).
Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).
Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).
Chemotherapy probably leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
Chemotherapy showed no clear difference in overall survival compared with biological therapy (moderate certainty).
Chemotherapy probably leads to higher progression‐free survival compared with biological therapy (moderate certainty).
Chemotherapy may leads to lower serious adverse events compared with biological therapy (low certainty).
Chemotherapy showed no clear difference in tumour response rate compared with biological therapy (low certainty).
Chemotherapy probably leads to lower any adverse events compared with biological therapy (moderate certainty).
Chemotherapy leads to lower progression‐free survival compared with placebo, best supportive care (BSC) or no treatment (high certainty).
Chemotherapy probably leads to higher serious adverse events compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
Chemotherapy showed no clear difference in tumour response rate compared with placebo, best supportive care (BSC) or no treatment (low certainty).